Walleye Capital’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.1M Buy
47,879
+44,677
+1,395% +$8.96M 0.01% 1264
2026
Q2
$609K Buy
+3,202
New +$550K ﹤0.01% 2546
2026
Q1
– Sell
-15,097
Closed -$2.55M – 4656
2025
Q4
$2.55M Buy
+15,097
New +$2.45M 0.01% 1676
2025
Q3
– Sell
-4,655
Closed -$589K – 4784
2025
Q2
$589K Buy
4,655
+985
+27% +$121K ﹤0.01% 2497
2025
Q1
$469K Sell
3,670
-4,588
-56% -$622K ﹤0.01% 2617
2024
Q4
$1.09M Sell
8,258
-760
-8% -$107K ﹤0.01% 2308
2024
Q3
$1.31M Buy
9,018
+4,082
+83% +$591K ﹤0.01% 2358
2024
Q2
$678K Sell
4,936
-4,064
-45% -$543K ﹤0.01% 3227
2024
Q1
$1.23M Buy
9,000
+6,301
+233% +$861K ﹤0.01% 2387
2023
Q4
$367K Buy
+2,699
New +$329K ﹤0.01% 3196

Other funds holding IBB

Walleye Capital's IBB Position: Q3 2026 in Review

Walleye Capital increased its iShares Biotechnology ETF (IBB) stake by 1,395% in Q3 2026, buying an estimated $8.96M and bringing the position to 47,879 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #1264.

Walleye Capital first reported a position in IBB in Q4 2023 and has held it in 10 quarters since. 1,024 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Walleye Capital held 47,879 shares of iShares Biotechnology ETF worth $10.1M as of Q3 2026.
  • Walleye Capital bought 44,677 iShares Biotechnology ETF shares in Q3 2026, an estimated $8.96M.
  • iShares Biotechnology ETF made up 0.01% of Walleye Capital's portfolio in Q3 2026, its #1264 holding.
  • Walleye Capital first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 10 quarters since.
  • 1,024 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.